The New Peptides Story: How GLP-1s Are Changing Mental Health
summary
Fountain Health reports that GLP‑1 drugs reduce cravings across addictions and quiet “food noise,” and that treating metabolic drivers (insulin resistance, hormones, micronutrients, sleep, body composition) changes outcomes for anxiety, depression and ADHD. Clinic workflow uses full labs, off‑label low‑dose GLP‑1s, ketamine to open a neuroplastic window, and multidisciplinary coaching; risks include rapid weight loss with bone loss. Flow aggregates labs, wearables and questionnaires to predict crises and track longitudinal biology. GLP‑3 trials show up to 30% weight loss.
AI-written summary · about
chapters (14)
- 0:00GLP-1s and mental health
- 1:04Fountain Health's care model
- 3:34Psychiatry's blind spots
- 5:24GLP-1s reduce cravings
- 6:29Biology and psyche balance
- 7:55GLP-1 risks and limits
- 8:38Before GLP-1s
- 10:45Ketamine + GLP-1s
- 13:32Treatment-resistant depression
- 14:57Patient education on biology
- 16:22Flow: scalable model
- 18:47Metabolic system improvements
- 20:32Future of body regulation
- 20:53GLP-3s and accessibility
related talks
07mAdd Years to Your Life
14mIt's Time To Talk About Precision Health
40mBringing mental health data to doctors
19mDeep Reinforcement Learning based Insulin Controller for Effective Type-1 Diabetic Care
38mBig data in personalised medicine
27mThe Future is Enhanced - How Sports, Longevity and Health Are Changing Now
20mTranslating a Trillion Pointo Diseases of Data into Therapies
30mMachine Learning: A New Approach to Drug Discovery